Jiangsu Yahong Meditech Co., Ltd.

Equities

688176

CNE100005XW0

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
6.16 ^CNY	-1.75%		-1.91%	-42.86%

Apr. 29	Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	CI

Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.

April 01, 2024

From February 6, 2024 to March 31, 2024, the company has repurchased 1,325,215 shares, representing 0.23% for CNY 8.14 million. With this, the company has completed the repurchase of 1,325,215 shares, representing 0.23% for CNY 8.14 million under the buyback announced on February 7, 2024.

Latest news about Jiangsu Yahong Meditech Co., Ltd.

Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	Apr. 01	CI
Asieris Pharmaceuticals Announces Release of Positive Results from Multicenter Phase III Global Clinical Study	Mar. 18	CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Asieris Pharmaceuticals to Unveil First-Ever Results of the International Multicenter Phase III Clinical Study for 1702, a Non-Surgical Treatment for Cervical HSIL, at the 2024 EUROGIN	Feb. 22	CI
Jiangsu Yahong Meditech to Buy Back Shares for Up to 100 Million Yuan	Feb. 12	MT
Jiangsu Yahong Meditech Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	Feb. 06	CI
Jiangsu Yahong Meditech Co., Ltd. authorizes a Buyback Plan.	Feb. 05	CI
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, A Bladder Cancer Diagnosis and Management Drug, At the 2024 ASCO-GU	Jan. 29	CI
Asieris Pharmaceuticals Announces Set-Up of the Women's Health Business Unit for Commercialization	Jan. 08	CI
Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit	Jan. 08	CI
Certain A Shares of Jiangsu Yahong Meditech Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-JAN-2024.	Jan. 06	CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Asieris Pharmaceuticals Unveils Results of Its Hexvix[®] (Apl-1706) Phase III Clinical Trial in China	23-10-12	CI
Photocure Partner Asieris Pharmaceuticals to Present First Results for its Hexvix Phase III Clinical Trial in China at the SIU2023 Annual Meeting	23-10-07	CI
Jiangsu Yahong Meditech Completes Phase III Trial Into APL1702 Drug; Shares Drop 4%	23-09-21	MT
Asieris Pharmaceuticals Announces the First Non-Vaccine Investigational Product for Cervical HSIL Has Achieved Its Primary Endpoint	23-09-20	CI
Jiangsu Yahong Meditech Co., Ltd.(XSSC:688176) added to S&P Global BMI Index	23-09-18	CI
Jiangsu Yahong Meditech Enrolls First Subjects for Ulcerative Colitis Drug Trial	23-09-15	MT
Jiangsu Yahong Meditech Gets Nod to Trial Ulcerative Colitis Drug	23-08-30	MT
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization	23-08-22	CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
Hong Kong Department of Health Approves the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System	23-08-15	CI
Asieris Pharmaceuticals Confirms Hexvix Phase III Clinical Trial in China Meet Endpoint	23-08-11	CI
Asieris Pharmaceuticals Announces Positive Phase III Bridging Trial of Hexvix(R), a Diagnostic Drug for Bladder Cancer	23-08-11	CI

Chart Jiangsu Yahong Meditech Co., Ltd.

Duration

Period

More charts

Company Profile

Jiangsu Yahong Meditech Co Ltd is a China-based company mainly engaged in drug research and development (R&D). The Company focuses on innovative drugs in the field of urogenital tumors and other major diseases. The product pipelines being developed by the Company include APL-1202, APL-1501, APL-1706, APL-1702, ASN-1764, ASN-1780, APL-1901, APL-1401, ASN-1733 and others. The Company is still in the R&D stage.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Jiangsu Yahong Meditech Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.16 CNY

Average target price

12.28 CNY

Spread / Average Target

+99.43%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
JIANGSU YAHONG MEDITECH CO., LTD.	-42.86%	494M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs